These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29245997)

  • 1. What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? a systematic review and network meta-analysis.
    Xie H; Yu H; Tian S; Yang X; Wang X; Yang Z; Wang H; Guo Z
    Oncotarget; 2017 Nov; 8(59):100508-100523. PubMed ID: 29245997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
    PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Kushen injection combined with TACE improve therapeutic efficacy and safety in patients with advanced HCC? a systematic review and network meta-analysis.
    Zhang Y; Hui F; Yang Y; Chu H; Qin X; Zhao M; Zhao Q
    Oncotarget; 2017 Dec; 8(63):107258-107272. PubMed ID: 29291026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis.
    Feng F; Jiang Q; Jia H; Sun H; Chai Y; Li X; Rong G; Zhang Y; Li Z
    Pharmacol Res; 2018 Sep; 135():89-101. PubMed ID: 29959032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
    Fu Y; Zhao X; Yun Q; Zhu X; Zhu Y; Li Q; Hu K; Wang J; Qiao Z
    Int J Clin Exp Med; 2015; 8(7):10388-400. PubMed ID: 26379829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy evaluation of the combination therapy of sorafenib and transarterial chemoembolization for unresectable HCC: a systematic review and meta-analysis of comparative studies.
    Li H; Li S; Geng J; Zhao S; Tan K; Yang Z; Feng D; Liu L
    Ann Transl Med; 2020 Apr; 8(8):540. PubMed ID: 32411763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta‑analysis.
    Li Y; Liu X; Liu J; Yang L; Wei S; Li J; Gan H; Ma T; Yi P
    Oncol Lett; 2024 Aug; 28(2):347. PubMed ID: 38872858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial chemoembolization combination therapy vs monotherapy in unresectable hepatocellular carcinoma: a meta-analysis.
    Li L; Tian J; Liu P; Wang X; Zhu Z
    Tumori; 2016 Jun; 2016(3):301-10. PubMed ID: 27002950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis.
    Long J; Chen B; Liu Z
    Front Oncol; 2023; 13():1179431. PubMed ID: 37265792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Yang M; Yuan JQ; Bai M; Han GH
    Mol Biol Rep; 2014 Oct; 41(10):6575-82. PubMed ID: 25091939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Is the Most Suitable Agent Combined With Apatinib for Transarterial Chemoembolization Treatment in Advanced Hepatocellular Carcinoma Patients? A Systematic Review and Network Meta-analysis.
    Hui F; Xu C; Xu X; Chen J; Geng H; Yang C; Zhang Y
    Front Oncol; 2022; 12():887332. PubMed ID: 35692745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant transarterial chemoembolization to sorafenib in unresectable hepatocellular carcinoma: A meta-analysis.
    Chen A; Li S; Yao Z; Hu J; Cao J; Topatana W; Juengpanich S; Yu H; Shen J; Chen M
    J Gastroenterol Hepatol; 2021 Feb; 36(2):302-310. PubMed ID: 32652685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial Chemoembolization Plus Sorafenib versus Transarterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma: An Umbrella Review of Meta-Analyses and Systematic Reviews.
    Yan J; Wen Y; Deng M; Ye B; Liu X; Zhang L
    J Hepatocell Carcinoma; 2023; 10():1723-1733. PubMed ID: 37817915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.
    Majumdar A; Roccarina D; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011650. PubMed ID: 28351116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.
    Qi X; Liu L; Wang D; Li H; Su C; Guo X
    Oncotarget; 2015 Nov; 6(34):36838-59. PubMed ID: 26451613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis.
    Wang W; Shi J; Xie WF
    Liver Int; 2010 May; 30(5):741-9. PubMed ID: 20331507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization with or without multikinase inhibitors for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis of randomized controlled trials.
    Dong H; Ge D; Qu B; Zhu P; Wu Q; Wang T; Wang J; Li Z
    Front Oncol; 2023; 13():1139025. PubMed ID: 37361570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis.
    Dai Y; Jiang H; Jiang H; Zhao S; Zeng X; Sun R; Zheng R
    Transl Oncol; 2021 Dec; 14(12):101238. PubMed ID: 34628285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Zeng J; Lv L; Mei ZC
    Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):688-697. PubMed ID: 27339594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.